ReviewIndian journal of ophthalmology2011
Neuroprotection in glaucoma.
Review in Indian journal of ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 66 citations in OpenAlex.
- Therapeutic Potential of Cannabinoids in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Beneficial effect of mindfulness based stress reduction on optic disc perfusion in primary open angle glaucoma: A randomized controlled trial.Journal of traditional and complementary medicine · 2021Article
- Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention.International journal of molecular sciences · 2021Review
- A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma.Advanced pharmaceutical bulletin · 2021Review
- Computational Analysis of Clinical and Molecular Markers and New Theranostic Possibilities in Primary Open-Angle Glaucoma.Journal of clinical medicine · 2020Article
- Dose-dependent effects of NMDA on retinal and optic nerve morphology in rats.International journal of ophthalmology · 2019Article
- Additive neuroprotective effects of 24(S)-hydroxycholesterol and allopregnanolone in an ex vivo rat glaucoma model.Scientific reports · 2018Article
- Physical activity, visual impairment, and eye disease.Eye (London, England) · 2018Review
- Neuroprotective agents in the management of glaucoma.Eye (London, England) · 2018Review
- Magnesium acethyltaurate as a potential agent for retinal and optic nerve protection in glaucoma.Neural regeneration research · 2018Article
- The Association between Female Reproductive Factors and Open-Angle Glaucoma in Korean Women: The Korean National Health and Nutrition Examination Survey V.Journal of ophthalmology · 2018Article
- Ocular Disposition of ∆AAPS PharmSciTech · 2017Article
- Glaucoma -state of the art and perspectives on treatment.Restorative neurology and neuroscience · 2016Review
- Mechanisms of secondary degeneration after partial optic nerve transection.Neural regeneration research · 2014Review
- Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome.Brain : a journal of neurology · 2014Article
- Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma.ClinicoEconomics and outcomes research : CEOR · 2014Review
- 17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma.Molecular pharmaceutics · 2013Article
- Reactive oxygen species, oxidative stress, glaucoma and hyperbaric oxygen therapy.Journal of optometryReview
- Biochemical changes and treatment in glaucoma.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a neurodegenerative disease characterized by loss of retinal ganglion cells and their axons. Recent evidence suggests that intraocular pressure (IOP) is only one of the many risk factors for this disease. Current treatment options for this disease have been limited to the reduction of IOP; however, it is clear now that the disease progression continues in many patients despite effective lowering of IOP. In the search for newer modalities in treating this disease, much data have emerged from experimental research the world over, suggesting various pathological processes involved in this disease and newer possible strategies to treat it. This review article looks into the current understanding of the pathophysiology of glaucoma, the importance of neuroprotection, the various possible pharmacological approaches for neuroprotection and evidence of current available medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.